Cover Image
市場調查報告書

單純皰疹病毒病 : 開發平台分析

Herpes Simplex Infections - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 232808
出版日期 內容資訊 英文 185 Pages
訂單完成後即時交付
價格
Back to Top
單純皰疹病毒病 : 開發平台分析 Herpes Simplex Infections - Pipeline Review, H2 2015
出版日期: 2015年09月23日 內容資訊: 英文 185 Pages
簡介

單純皰疹病毒(HSV)是引起皰疹的感染源。皰疹會以性器、口腔為中心,在人體各個部位出現。主要的症狀有水疱或潰瘍、頸部或鼠蹊部的淋巴結肥大化、單純皰疹、發燒等。主要治療方法有抗真菌劑等。致病因子有免疫系統低落及性行為傳染等。

本報告提供全球各國治療單純皰疹(單純皰疹)感染疾病用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

單純皰疹病毒病概要

治療藥的開發

  • 單純皰疹病毒病開發中產品:概要
  • 單純皰疹病毒病開發中產品:比較分析

各企業開發中的單純皰疹病毒病治療藥

大學/研究機關研究中的單純皰疹病毒病治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

單純皰疹病毒病治療藥:開發中的產品的一覽(各企業)

單純皰疹病毒病治療藥:研究中的產品的一覽(大學/研究機關別)

單純皰疹病毒病治療藥的開發企業

  • 3-V Biosciences, Inc.
  • Adamis Pharmaceuticals Corporation
  • Admedus Ltd
  • AiCuris GmbH & Co. KG
  • Astellas Pharma Inc.
  • Beech Tree Labs, Inc.
  • CEL-SCI Corporation
  • Chimerix, Inc.
  • Epiphany Biosciences, Inc.
  • Foamix Pharmaceuticals Ltd.
  • Genocea Biosciences, Inc.
  • GenVec, Inc.
  • Immune Design Corp.
  • Immunovaccine, Inc.
  • JN-International Medical Corporation
  • Microbiotix, Inc.
  • Mymetics Corporation
  • NanoBio Corporation
  • NanoViricides, Inc.
  • Onxeo SA
  • Oryzon Genomics S.A.
  • Osel Inc.
  • PaxVax
  • Peregrine Pharmaceuticals, Inc.
  • Profectus BioSciences, Inc.
  • Romark Laboratories, L.C.
  • Sanofi
  • Sanofi Pasteur SA
  • Shulov Innovative Science Ltd.
  • Spider Biotech
  • Starpharma Holdings Limited
  • Vaccibody AS
  • Vaxart, Inc.
  • Vical Incorporated
  • Vironova AB
  • ViroStatics, srl

單純皰疹病毒病:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (celecoxib + famciclovir)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 熱威樂素錠
  • amenamevir
  • Aspidasept
  • astodrimer
  • 感染疾病治療藥
  • brincidofovir
  • BTL-TMLHSV
  • C-31G
  • CEL-1000
  • G-103
  • GEN-002
  • GEN-003
  • 生殖器皰疹疫苗HSV-2
  • GV-2207
  • Herpecide
  • 單純皰疹病毒病 2形式 疫苗
  • 單純皰疹病毒病 1, 2形式 疫苗
  • 單純皰疹病毒病 第一型 疫苗
  • HSV 疫苗
  • HSV-529
  • MB-66
  • MBX-2168
  • HIV·單純皰疹病毒病的單株抗體
  • 單純皰疹病毒病的單株抗體
  • HIV·HSV感染疾病胜肽
  • PGN-632
  • pritelivir
  • RC-100b
  • RKP-00156
  • SB-105
  • SB-105A10
  • EBV·HSV感染疾病CDK4·CDK6·CDK9阻礙小分子
  • HSV感染疾病LSD-1阻礙小分子
  • RS病毒·單純皰疹病毒病小分子
  • 病毒感染小分子
  • 病毒感染脂肪酸shintaze標的小分子
  • 流感,HSV· HIV感染疾病合成胜肽
  • 腫瘤學·感染疾病合成胜肽
  • 病毒感染合成胜肽
  • Teg-379
  • UB-621
  • valomaciclovir stearate
  • VCLHB-01
  • VCLHM-01
  • VN-180
  • ZEP-3

單純皰疹病毒病治療藥:開發中產品的最新趨勢

單純皰疹病毒病治療藥:暫停開發的產品

單純皰疹病毒病治療藥:中止開發的產品

單純皰疹病毒病相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7082IDB

Summary

Global Markets Direct's, 'Herpes Simplex Infections - Pipeline Review, H2 2015', provides an overview of the Herpes Simplex Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Herpes Simplex Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Herpes Simplex Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Herpes Simplex Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Herpes Simplex Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Herpes Simplex Infections Overview
  • Therapeutics Development
    • Pipeline Products for Herpes Simplex Infections - Overview
    • Pipeline Products for Herpes Simplex Infections - Comparative Analysis
  • Herpes Simplex Infections - Therapeutics under Development by Companies
  • Herpes Simplex Infections - Therapeutics under Investigation by Universities/Institutes
  • Herpes Simplex Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Herpes Simplex Infections - Products under Development by Companies
  • Herpes Simplex Infections - Products under Investigation by Universities/Institutes
  • Herpes Simplex Infections - Companies Involved in Therapeutics Development
    • 3-V Biosciences, Inc.
    • Adamis Pharmaceuticals Corporation
    • Admedus Ltd
    • AiCuris GmbH & Co. KG
    • Astellas Pharma Inc.
    • Beech Tree Labs, Inc.
    • CEL-SCI Corporation
    • Chimerix, Inc.
    • Epiphany Biosciences, Inc.
    • Foamix Pharmaceuticals Ltd.
    • Genocea Biosciences, Inc.
    • GenVec, Inc.
    • Immune Design Corp.
    • Immunovaccine, Inc.
    • JN-International Medical Corporation
    • Microbiotix, Inc.
    • Mymetics Corporation
    • NanoBio Corporation
    • NanoViricides, Inc.
    • Onxeo SA
    • Oryzon Genomics S.A.
    • Osel Inc.
    • PaxVax
    • Peregrine Pharmaceuticals, Inc.
    • Profectus BioSciences, Inc.
    • Romark Laboratories, L.C.
    • Sanofi
    • Sanofi Pasteur SA
    • Shulov Innovative Science Ltd.
    • Spider Biotech
    • Starpharma Holdings Limited
    • Vaccibody AS
    • Vaxart, Inc.
    • Vical Incorporated
    • Vironova AB
    • ViroStatics, srl
  • Herpes Simplex Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (celecoxib + famciclovir) - Drug Profile
    • acyclovir - Drug Profile
    • acyclovir - Drug Profile
    • amenamevir - Drug Profile
    • Aspidasept - Drug Profile
    • astodrimer - Drug Profile
    • Biologic for Infectious Disease - Drug Profile
    • brincidofovir - Drug Profile
    • BTL-TMLHSV - Drug Profile
    • C-31G - Drug Profile
    • CEL-1000 - Drug Profile
    • G-103 - Drug Profile
    • GEN-002 - Drug Profile
    • GEN-003 - Drug Profile
    • genital herpes vaccine [HSV-2] - Drug Profile
    • GV-2207 - Drug Profile
    • Herpecide - Drug Profile
    • herpes simplex virus [serotype 2] vaccine - Drug Profile
    • herpes simplex virus [type 1, 2] vaccine - Drug Profile
    • herpes simplex virus [type 1] vaccine - Drug Profile
    • herpes simplex virus [type 2] vaccine - Drug Profile
    • herpes simplex virus [type 2] vaccine - Drug Profile
    • herpes simplex virus [type 2] vaccine - Drug Profile
    • herpes simplex virus [type 2] vaccine - Drug Profile
    • herpes simplex virus [type 2] vaccine - Drug Profile
    • herpes simplex virus [type 2] vaccine - Drug Profile
    • herpes simplex virus [type 2] vaccine - Drug Profile
    • herpes simplex virus [type 2] vaccine - Drug Profile
    • herpes simplex virus [type 2] vaccine - Drug Profile
    • HSV vaccine - Drug Profile
    • HSV-529 - Drug Profile
    • MB-66 - Drug Profile
    • MBX-2168 - Drug Profile
    • Monoclonal Antibodies for HIV and Herpes Simplex Infections - Drug Profile
    • Monoclonal Antibody for Herpes Simplex Infections - Drug Profile
    • Monoclonal Antibody for Herpes Simplex Infections - Drug Profile
    • Peptide for HIV and HSV Infections - Drug Profile
    • PGN-632 - Drug Profile
    • pritelivir - Drug Profile
    • RC-100b - Drug Profile
    • RKP-00156 - Drug Profile
    • SB-105 - Drug Profile
    • SB-105A10 - Drug Profile
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV and HSV Infections - Drug Profile
    • Small Molecule to Inhibit LSD-1 for HSV - Drug Profile
    • Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections - Drug Profile
    • Small Molecules for Viral Infections - Drug Profile
    • Small Molecules to Inhibit Fatty Acid Synthase for Viral Infections - Drug Profile
    • Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
    • Synthetic Peptides for Oncology and Infectious Disease - Drug Profile
    • Synthetic Peptides for Viral Infections - Drug Profile
    • Teg-379 - Drug Profile
    • UB-621 - Drug Profile
    • valomaciclovir stearate - Drug Profile
    • VCLHB-01 - Drug Profile
    • VCLHM-01 - Drug Profile
    • VN-180 - Drug Profile
    • ZEP-3 - Drug Profile
  • Herpes Simplex Infections - Recent Pipeline Updates
  • Herpes Simplex Infections - Dormant Projects
  • Herpes Simplex Infections - Discontinued Products
  • Herpes Simplex Infections - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Herpes Simplex Infections, H2 2015
  • Number of Products under Development for Herpes Simplex Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Herpes Simplex Infections - Pipeline by 3-V Biosciences, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015
  • Herpes Simplex Infections - Pipeline by Admedus Ltd, H2 2015
  • Herpes Simplex Infections - Pipeline by AiCuris GmbH & Co. KG, H2 2015
  • Herpes Simplex Infections - Pipeline by Astellas Pharma Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Beech Tree Labs, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by CEL-SCI Corporation, H2 2015
  • Herpes Simplex Infections - Pipeline by Chimerix, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Epiphany Biosciences, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
  • Herpes Simplex Infections - Pipeline by Genocea Biosciences, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by GenVec, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Immune Design Corp., H2 2015
  • Herpes Simplex Infections - Pipeline by Immunovaccine, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by JN-International Medical Corporation, H2 2015
  • Herpes Simplex Infections - Pipeline by Microbiotix, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Mymetics Corporation, H2 2015
  • Herpes Simplex Infections - Pipeline by NanoBio Corporation, H2 2015
  • Herpes Simplex Infections - Pipeline by NanoViricides, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Onxeo SA, H2 2015
  • Herpes Simplex Infections - Pipeline by Oryzon Genomics S.A., H2 2015
  • Herpes Simplex Infections - Pipeline by Osel Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by PaxVax, H2 2015
  • Herpes Simplex Infections - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Profectus BioSciences, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Romark Laboratories, L.C., H2 2015
  • Herpes Simplex Infections - Pipeline by Sanofi, H2 2015
  • Herpes Simplex Infections - Pipeline by Sanofi Pasteur SA, H2 2015
  • Herpes Simplex Infections - Pipeline by Shulov Innovative Science Ltd., H2 2015
  • Herpes Simplex Infections - Pipeline by Spider Biotech, H2 2015
  • Herpes Simplex Infections - Pipeline by Starpharma Holdings Limited, H2 2015
  • Herpes Simplex Infections - Pipeline by Vaccibody AS, H2 2015
  • Herpes Simplex Infections - Pipeline by Vaxart, Inc., H2 2015
  • Herpes Simplex Infections - Pipeline by Vical Incorporated, H2 2015
  • Herpes Simplex Infections - Pipeline by Vironova AB, H2 2015
  • Herpes Simplex Infections - Pipeline by ViroStatics, srl, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Herpes Simplex Infections Therapeutics - Recent Pipeline Updates, H2 2015
  • Herpes Simplex Infections - Dormant Projects, H2 2015
  • Herpes Simplex Infections - Dormant Projects (Contd..1), H2 2015
  • Herpes Simplex Infections - Dormant Projects (Contd..2), H2 2015
  • Herpes Simplex Infections - Dormant Projects (Contd..3), H2 2015
  • Herpes Simplex Infections - Dormant Projects (Contd..4), H2 2015
  • Herpes Simplex Infections - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Herpes Simplex Infections, H2 2015
  • Number of Products under Development for Herpes Simplex Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top